FR2823209B1 - Nouvelles thiohydantoines et leur utilisation en therapeutique - Google Patents

Nouvelles thiohydantoines et leur utilisation en therapeutique

Info

Publication number
FR2823209B1
FR2823209B1 FR0104552A FR0104552A FR2823209B1 FR 2823209 B1 FR2823209 B1 FR 2823209B1 FR 0104552 A FR0104552 A FR 0104552A FR 0104552 A FR0104552 A FR 0104552A FR 2823209 B1 FR2823209 B1 FR 2823209B1
Authority
FR
France
Prior art keywords
thiohydantoins
therapeutics
novel
novel thiohydantoins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0104552A
Other languages
English (en)
Other versions
FR2823209A1 (fr
Inventor
Benaissa Boubia
Evelyne Chaput
Khan Ou
Philippe Ratel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratories Fournier SAS
Original Assignee
Laboratories Fournier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0104552A priority Critical patent/FR2823209B1/fr
Application filed by Laboratories Fournier SAS filed Critical Laboratories Fournier SAS
Priority to HU0401537A priority patent/HUP0401537A3/hu
Priority to MXPA03009083A priority patent/MXPA03009083A/es
Priority to YU75903A priority patent/YU75903A/sh
Priority to CZ20032696A priority patent/CZ20032696A3/cs
Priority to US10/473,032 priority patent/US20040116417A1/en
Priority to JP2002579441A priority patent/JP2004525175A/ja
Priority to CNA028075811A priority patent/CN1500081A/zh
Priority to EP02730333A priority patent/EP1373219A1/fr
Priority to RU2003129532/04A priority patent/RU2003129532A/ru
Priority to PL02364904A priority patent/PL364904A1/xx
Priority to PCT/FR2002/001167 priority patent/WO2002081453A1/fr
Priority to KR10-2003-7012356A priority patent/KR20030085565A/ko
Priority to CA002444024A priority patent/CA2444024A1/fr
Priority to BR0207910-0A priority patent/BR0207910A/pt
Priority to SK1233-2003A priority patent/SK12332003A3/sk
Priority to IL15819502A priority patent/IL158195A0/xx
Priority to EEP200300485A priority patent/EE200300485A/xx
Publication of FR2823209A1 publication Critical patent/FR2823209A1/fr
Priority to ZA200307372A priority patent/ZA200307372B/en
Priority to BG108225A priority patent/BG108225A/xx
Priority to NO20034430A priority patent/NO20034430L/no
Application granted granted Critical
Publication of FR2823209B1 publication Critical patent/FR2823209B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
FR0104552A 2001-04-04 2001-04-04 Nouvelles thiohydantoines et leur utilisation en therapeutique Expired - Fee Related FR2823209B1 (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
FR0104552A FR2823209B1 (fr) 2001-04-04 2001-04-04 Nouvelles thiohydantoines et leur utilisation en therapeutique
BR0207910-0A BR0207910A (pt) 2001-04-04 2002-04-04 HidantÈnios e sua utilização no tratamento do diabetes
CA002444024A CA2444024A1 (fr) 2001-04-04 2002-04-04 Hiohydantoines et leur utilisation dans le traitement du diabete
CZ20032696A CZ20032696A3 (cs) 2001-04-04 2002-04-04 Thiohydantoiny a jejich použití při léčení cukrovky
MXPA03009083A MXPA03009083A (es) 2001-04-04 2002-04-04 Tiohidantoinas y su utilizacion en el tratamiento de diabetes.
JP2002579441A JP2004525175A (ja) 2001-04-04 2002-04-04 チオヒダントイン及び糖尿病治療のためのその使用
CNA028075811A CN1500081A (zh) 2001-04-04 2002-04-04 乙内酰硫脲及其在治疗糖尿病方面的用途
SK1233-2003A SK12332003A3 (sk) 2001-04-04 2002-04-04 Tiohydantoíny a ich použitie na liečenie cukrovky
RU2003129532/04A RU2003129532A (ru) 2001-04-04 2002-04-04 Тиогидантоины и их применение при лечении диабета
PL02364904A PL364904A1 (en) 2001-04-04 2002-04-04 Thiohydantoins and use thereof for treating diabetes
HU0401537A HUP0401537A3 (en) 2001-04-04 2002-04-04 Thiohydantoins, process for their preparation, pharmaceutical compositions containing them and use thereof for preparation of pharmaceutical compositions
KR10-2003-7012356A KR20030085565A (ko) 2001-04-04 2002-04-04 티오하이단토인 유도체 및 당뇨병 치료를 위한 이들의 용도
YU75903A YU75903A (sh) 2001-04-04 2002-04-04 Tiohidantoini i njihovo korišćenje u lečenju dijabetisa
US10/473,032 US20040116417A1 (en) 2001-04-04 2002-04-04 Thiohydantoins and use thereof for treating diabetes
EP02730333A EP1373219A1 (fr) 2001-04-04 2002-04-04 Thiohydantoines et leur utilisation dans le traitement du diabete
IL15819502A IL158195A0 (en) 2001-04-04 2002-04-04 Thiohydantoins and use thereof for treating diabetes
EEP200300485A EE200300485A (et) 2001-04-04 2002-04-04 Tiohüdantoinid ja nende kasutamine diabeedi raviks
PCT/FR2002/001167 WO2002081453A1 (fr) 2001-04-04 2002-04-04 Hiohydantoïnes et leur utilisation dans le traitement du diabete
ZA200307372A ZA200307372B (en) 2001-04-04 2003-09-22 Thiohydantoins and use thereof for treating diabetes.
BG108225A BG108225A (en) 2001-04-04 2003-10-03 Thiohydantoins and use thereof for treating diabetes
NO20034430A NO20034430L (no) 2001-04-04 2003-10-03 Tiohydantoiner og anvendelse derav for behandling av diatbetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0104552A FR2823209B1 (fr) 2001-04-04 2001-04-04 Nouvelles thiohydantoines et leur utilisation en therapeutique

Publications (2)

Publication Number Publication Date
FR2823209A1 FR2823209A1 (fr) 2002-10-11
FR2823209B1 true FR2823209B1 (fr) 2003-12-12

Family

ID=8861916

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0104552A Expired - Fee Related FR2823209B1 (fr) 2001-04-04 2001-04-04 Nouvelles thiohydantoines et leur utilisation en therapeutique

Country Status (21)

Country Link
US (1) US20040116417A1 (fr)
EP (1) EP1373219A1 (fr)
JP (1) JP2004525175A (fr)
KR (1) KR20030085565A (fr)
CN (1) CN1500081A (fr)
BG (1) BG108225A (fr)
BR (1) BR0207910A (fr)
CA (1) CA2444024A1 (fr)
CZ (1) CZ20032696A3 (fr)
EE (1) EE200300485A (fr)
FR (1) FR2823209B1 (fr)
HU (1) HUP0401537A3 (fr)
IL (1) IL158195A0 (fr)
MX (1) MXPA03009083A (fr)
NO (1) NO20034430L (fr)
PL (1) PL364904A1 (fr)
RU (1) RU2003129532A (fr)
SK (1) SK12332003A3 (fr)
WO (1) WO2002081453A1 (fr)
YU (1) YU75903A (fr)
ZA (1) ZA200307372B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
WO2004009558A2 (fr) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Composes d'acide benzoique a substitution ureido et leur utilisation pour la suppression de non-sens et le traitement de maladie
ITMI20022748A1 (it) * 2002-12-23 2004-06-24 Eurand Int Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione.
ES2397389T3 (es) 2003-07-30 2013-03-06 Xenon Pharmaceuticals Inc. Derivados de piridilo y su uso como agentes terapéuticos
AR047557A1 (es) 2003-07-30 2006-01-25 Xenon Pharmaceuticals Inc Compuestos derivados de piridazina y su uso como agentes terapeuticos
US8034548B2 (en) * 2003-12-19 2011-10-11 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
AU2005232526B2 (en) 2004-02-24 2011-06-23 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
DE102004024011A1 (de) * 2004-05-14 2005-12-01 Bayer Chemicals Ag Difluorbenzo-1,3-dioxole
CN101083986A (zh) * 2004-09-20 2007-12-05 泽农医药公司 双环杂环衍生物及其作为硬脂酰CoA去饱和酶(SCD)抑制剂的用途
AU2005286728A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP1830837B1 (fr) 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Derives heterocycliques pour le traitement de maladies induites par des enzymes stearoyl-coadesaturases
AR051090A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
AU2005286648A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
BRPI0515482A (pt) * 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
WO2006034446A2 (fr) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation comme agents therapeutiques
AR051094A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
JP2009513563A (ja) * 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体
HUE027894T2 (en) * 2006-03-27 2016-11-28 Univ California An androgen receptor modulator for the treatment of prostate cancer and androgen receptor related diseases
AU2016201061B2 (en) * 2006-03-27 2017-03-02 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
KR101456722B1 (ko) * 2006-03-29 2014-10-31 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴티오히단토인 화합물
WO2008021338A2 (fr) 2006-08-15 2008-02-21 Wyeth Dérivés d'oxazolidone tricycliques utiles en tant que modulateurs du récepteur de la progestérone
TW200815428A (en) 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
US7652018B2 (en) 2006-08-15 2010-01-26 Wyeth Llc Imidazolidin-2-one derivatives useful as PR modulators
WO2008021337A1 (fr) 2006-08-15 2008-02-21 Wyeth Dérivés oxazinan-2-one utiles comme modulateurs pr
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
FR2917735B1 (fr) * 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
PE20121470A1 (es) 2007-10-26 2012-11-18 Univ California Compuestos de diarilhidantoina como antagonistas del receptor de androgeno
WO2009145286A1 (fr) 2008-05-30 2009-12-03 武田薬品工業株式会社 Composé hétérocyclique
MX2011011964A (es) 2009-05-12 2012-02-23 Janssen Pharmaceuticals Inc Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos.
EA028869B1 (ru) * 2010-02-16 2018-01-31 Арагон Фармасьютикалс, Инк. Модуляторы рецептора андрогенов и их применение
PT2538785T (pt) * 2010-02-24 2018-05-09 Medivation Prostate Therapeutics Llc Processos para a síntese de compostos de diariltiohidantoína e diarilhidantoína
WO2013067142A1 (fr) * 2011-11-02 2013-05-10 Medivation Technologies, Inc. Composés et méthodes de traitement
CN104661658A (zh) 2012-09-26 2015-05-27 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
ITUB20151256A1 (it) 2015-05-28 2016-11-28 Olon Spa Processo industriale per la preparazione di enzalutamide
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN111479560A (zh) 2017-10-16 2020-07-31 阿拉贡药品公司 用于治疗非转移性去势难治性前列腺癌的抗雄激素
CN117120436A (zh) * 2021-03-30 2023-11-24 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2551134A (en) * 1947-05-15 1951-05-01 Du Pont Process of color developing with 2-thiohydantoin derivatives
US3923994A (en) * 1973-07-13 1975-12-02 Smithkline Corp Anti-arthritic compositions comprising a 3-aryl 2-thiohydantoin and methods of producing anti-arthritic acitvity
GB1472467A (en) * 1974-04-19 1977-05-04 Wyeth John & Brother Ltd Thiohydantoins
US4473393A (en) * 1982-08-06 1984-09-25 Buffalo Color Corporation Pesticidal thiohydantoin compositions
US4743611A (en) * 1986-07-02 1988-05-10 American Home Products Corp. Naphthalenylsulfonylimidazolidinediones and their thioxo analogs useful as aldose reductase inhibitors
US5554607A (en) * 1995-11-28 1996-09-10 American Home Products Corporation Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis
US5821372A (en) * 1995-11-28 1998-10-13 American Home Products Corporation 2-thioxo-imidazolidin-4-one derivatives
DE19741235A1 (de) * 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
HUP0401537A3 (en) 2005-06-28
FR2823209A1 (fr) 2002-10-11
SK12332003A3 (sk) 2004-04-06
CZ20032696A3 (cs) 2003-12-17
KR20030085565A (ko) 2003-11-05
BG108225A (en) 2005-04-30
PL364904A1 (en) 2004-12-27
WO2002081453A1 (fr) 2002-10-17
EE200300485A (et) 2004-02-16
JP2004525175A (ja) 2004-08-19
CN1500081A (zh) 2004-05-26
NO20034430D0 (no) 2003-10-03
HUP0401537A2 (hu) 2005-01-28
YU75903A (sh) 2006-05-25
US20040116417A1 (en) 2004-06-17
BR0207910A (pt) 2004-08-03
IL158195A0 (en) 2004-03-28
EP1373219A1 (fr) 2004-01-02
WO2002081453A8 (fr) 2002-11-14
NO20034430L (no) 2003-10-06
ZA200307372B (en) 2004-09-22
CA2444024A1 (fr) 2002-10-17
RU2003129532A (ru) 2005-04-10
MXPA03009083A (es) 2004-11-22

Similar Documents

Publication Publication Date Title
FR2823209B1 (fr) Nouvelles thiohydantoines et leur utilisation en therapeutique
MA26348A1 (fr) 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine substituees et leur utilisation
DE60142955D1 (de) Batterieladeverfahren und batterieblock
EE200200372A (et) VLA-4 sõltuva raku seostumise mittepeptiidsed inhibiitorid, mis on kasutatavad põletiku-, autoimmuun- ja respiratoorsete haiguste raviks
NO20024099L (no) Lavdose entecavir-formulering og anvendelse
IS6411A (is) Kaspasa tálmar og notkun þeirra
DE60135173D1 (de) Spielsystem und computerlesbares Speichermedium
DE60111534D1 (de) Alpha-acyl- und alpha-heteroatom-substituierte benzenacetamide verwendbar als glucokinase-aktivatoren
DK1122244T3 (da) Uracilforbindelser og anvendelse deraf
NO20022334L (no) Ny sammensetning og anvendelse
DE60111422D1 (de) Erkennung von merkmalen in bildern
PT1326853E (pt) Novos tiadiazoles e oxadiazoles e sua utilizacao como inibidores da fosfodiesterase-7
ID24963A (id) Celana dalam yang dapat dibuang setelah sekali pemakaian
NO20014100L (no) Polyalken alkoholpolyalkoksylater og anvendelse derav i drivstoff og smöremidler
DK0898566T3 (da) Substituerede benzylaminer og anvendelse deraf til behandling af depression
DE60134575D1 (de) Kombination enthaltend einen at1-rezeptor antagonisten und einen insulinsekretion verstärker oder einen insulin sensibilisator
GB0323954D0 (en) Block copolymer and use thereof
EP1700627A4 (fr) Systeme de jeu de cartes et carte utilisees dans ce systeme
FR2845384B1 (fr) Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR2838960B1 (fr) Composition comprenant des photochromes et son utilisation en cosmetique
MA26894A1 (fr) Agents antihypertenseurs et leur utilisation
NO20011371D0 (no) Kjemokinreseptorantagonist og cyklosporin i kombinert terapi
FR2845385B1 (fr) Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR2803523B1 (fr) Nouvelles compositions a base d'extraits de dictyotales et leur utilisation
FR2840899B1 (fr) Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20061230